Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
Launched by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE · Apr 9, 2020
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to treating patients with incurable diseases by using a special group called the Evolutionary Tumor Board (ETB). The ETB is made up of various experts who work together to develop personalized treatment strategies for patients who do not have standard options that can cure their illness. This trial aims to see how effective these tailored strategies can be for patients who are at high risk of their disease returning or who have not responded well to past treatments.
To be eligible for this study, participants should have a life expectancy of more than three months and be considered likely incurable by standard care. This includes patients in remission but still at high risk or those who have had limited success with previous therapies. Participants will need to agree to be monitored over time, which involves providing clinical information like scans and blood samples. Importantly, there are no specific exclusions, so many patients with complex conditions may be able to participate. Through this trial, patients can expect to receive innovative treatment ideas that may improve their quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
- • Participant must have a life expectancy greater than 3 months
- • Participant must have an ECOG performance status 0-2
- • Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
- • Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.
- Exclusion Criteria:
- • None
About H. Lee Moffitt Cancer Center And Research Institute
H. Lee Moffitt Cancer Center and Research Institute is a leading institution dedicated to cancer research, treatment, and education, recognized for its commitment to advancing cancer care through innovative clinical trials and groundbreaking research. As a National Cancer Institute-designated Comprehensive Cancer Center, Moffitt integrates cutting-edge science with patient-centered care, offering a multidisciplinary approach to cancer treatment. The center is at the forefront of developing novel therapies and improving outcomes for patients, emphasizing collaboration between researchers and clinicians to translate scientific discoveries into effective treatments. Through its extensive clinical trial programs, Moffitt aims to enhance the understanding of cancer biology and provide patients with access to the latest therapies and interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Tampa, Florida, United States
Patients applied
Trial Officials
Jingsong Zhang, MD
Principal Investigator
Moffitt Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials